To further explore the function of PPAR signaling pathway in tumorigenesis, we treated tumor-derived organoids with the drug FH535, which is a Wnt/β-catenin signaling pathway inhibitor and a dual PPARγ and PPARδ antagonist (Fig. 3C–E and Additional file 2: Fig. S5A-C). This evidence concerns the gene PPARD and neoplasm.